||Test name and Information (one sentence only)
||Clinical Significance of the Test in Clinical Practice
||ADRB2 GENOTYPING FOR B-2-AGONIST RESPONSIVENESS
||To identify haplotypes of the ADRB2 gene that may have clinical implications for asthma severity, cardiovascular function, obesity, and response to beta-agonist
||Alpha-1 Antitrypsin, Genotyping
||To confirm affected or carrier status in individuals with a serum AAT concentration less than 100 mg/dL. To determine affected or carrier status in individuals with a family history of AAT caused by the S or Z alleles.Prenatal diagnosis in foetuses, whose parents are both known carriers of the Z allele.
||COMT (Catechol-O-methyltransferase )Genotyping
||Investigation of inhibitor dosing for decreasing L-DOPA metabolism.
||Cytochrome P450 2C19 Genotype
||Dosing drugs that are metabolized by CYP2C19 may require adjustment based on the individual patient's genotype
||Cytochrome P450 2D6 (CYP2D6)
||Pretherapeutic testing to identify individuals who should avoid or have different dosing of medications metabolized by CYP2D6
||Warfarin Sensitivity by Genotyping (CYP2C9*2,CYP2C9*3 &VKORC1)
||Aids in warfarin dosage planning in conjunction with VKORC1 testing. If individualized warfarin dosage recommendations are required.